<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394481</url>
  </required_header>
  <id_info>
    <org_study_id>2020-000611-74</org_study_id>
    <nct_id>NCT04394481</nct_id>
  </id_info>
  <brief_title>Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery</brief_title>
  <acronym>INDEX</acronym>
  <official_title>Extension of the Analgesia of an Interscalene Block of the Brachial Plexus by Combined Injection of Dexamethasone and Dexmedetomidine, After Arthroscopic Shoulder Surgery: Randomized, Controlled, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Euraxi Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to demonstrate the efficacy of Dexmedetomidine on the&#xD;
      prolongation of analgesia obtained by interscalenic bloc of the brachial plexus and&#xD;
      intravenous injection of Dexamethasone (efficacy objective).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, comparative, randomized, controlled study versus reference&#xD;
      treatment, in 2 parallel groups, double blind (patient and evaluator), multicenter, aiming to&#xD;
      demonstrate the superiority of This is an interventional, comparative, randomized, controlled&#xD;
      study versus reference treatment, in 2 parallel groups, double blind (patient and evaluator),&#xD;
      multicenter, aiming to demonstrate the superiority of Dexmedetomidine over the absence of&#xD;
      Dexmedetomidine, in adjuvantation of a loco regional anesthesia (interscalenic bloc of the&#xD;
      brachial plexus + intravenous injection of Dexamethasone), on the prolongation of the&#xD;
      analgesia, following a surgery of the rotator cuff of the shoulder under arthroscopy.&#xD;
&#xD;
      Patients will be randomized into 2 groups according to the treatment received:&#xD;
&#xD;
        -  Dexmedetomidine;&#xD;
&#xD;
        -  Nothing (control arm). The investigator (anesthesiologist) who will perform the&#xD;
           randomization will not be blinded to the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of dexmedetomidine in prolonging analgesia</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between the start of the loco regional anesthésia (Hour 0) and the first post-operative oral morphine intake.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the motor block</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between Hour 0 (H0) and the moment when the patient can move his/her forearm and / or his/her arm again</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the sensitive block</measure>
    <time_frame>96 hours</time_frame>
    <description>Delay between H0 and the moment when the patient claims to have started to experience paraesthesia on his/her shoulder after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical scale from 0 to 10</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain scores at rest and in motion estimated by the patient at Hour 4 (H4), Hour 12 (H12), Hour 24 (H24) and Hour 48 (H48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral opioid analgesics</measure>
    <time_frame>48 hours</time_frame>
    <description>Cumulative amount of oral opioid analgesics taken during the 48 hours post-operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis</measure>
    <time_frame>96 hours</time_frame>
    <description>Evaluation of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-level Likert scale</measure>
    <time_frame>96 hours</time_frame>
    <description>Patient satisfaction with regard to analgesia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>DMD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>IV injection (1 µg/kg - 100 mL) before anesthetic induction</description>
    <arm_group_label>DMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Perinervous injection between C5 and C6 nerve roots / interscalene block (0.75% - 20 mL)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>DMD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>IV injection (0.15 mg/kg) during anesthetic induction</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>DMD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Patient undergoing arthroscopic shoulder surgery to repair the rotator cuff tendons;&#xD;
&#xD;
          -  Patient capable of understanding the information related to the study, of reading the&#xD;
             information leaflet and agreeing to sign the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient on oral morphines before surgery;&#xD;
&#xD;
          -  Contraindication to performing a general anesthesia associated with a shoulder loco&#xD;
             regional anesthesia in a single injection;&#xD;
&#xD;
          -  Contraindication to take oral morphines;&#xD;
&#xD;
          -  Any non-arthroscopic repair (intraoperative conversion to &quot;open sky&quot; technique);&#xD;
&#xD;
          -  Any other loco regional anesthesia than an interscalenic block (change of&#xD;
             intraoperative strategy);&#xD;
&#xD;
          -  Pregnant or lactating woman;&#xD;
&#xD;
          -  Intolerance or allergy or contraindication to one of the treatments under study;&#xD;
&#xD;
          -  Patient participating in another clinical trial, or in a period of exclusion from&#xD;
             another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien CABATON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien CABATON, MD</last_name>
    <phone>06 16 87 79 19</phone>
    <email>jucabaton@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital privé jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien MD CABATON</last_name>
      <email>jucabaton@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

